Prolonged continuous theta burst stimulation increases motor corticospinal excitability and intracortical inhibition in patients with neuropathic pain: An exploratory, single-blinded, randomized controlled trial

• Published in: Neurophysiologie clinique Vol. 53; no. 4; p. 102894
• Main Authors: Thakkar, Bhushan, Peterson, Carrie L., Acevedo, Edmund O.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-08-2023
• Subjects: Adult; Aged; Chronic pain; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - physiopathology; Diabetes Mellitus, Type 2 - therapy; Diabetic Neuropathies - physiopathology; Diabetic Neuropathies - therapy; Dorsolateral prefrontal cortex; Evoked Potentials, Motor - physiology; Female; Humans; Intracortical inhibition; Male; Middle Aged; Motor Cortex - physiopathology; Neural Inhibition - physiology; Neuralgia - physiopathology; Neuralgia - therapy; Neuromodulation; Primary motor cortex; Pyramidal Tracts - physiopathology; Single-Blind Method; Theta Rhythm - physiology; Transcranial Magnetic Stimulation - methods; Primary motor cortex; Dorsolateral prefrontal cortex; Intracortical inhibition; Neuromodulation; Chronic pain
• ISSN: 0987-7053; 1769-7131; 1769-7131
• DOI: 10.1016/j.neucli.2023.102894

A new paradigm for Transcranial Magnetic Stimulation (TMS), referred to as prolonged continuous theta burst stimulation (pcTBS), has recently received attention in the literature because of its advantages over high frequency repetitive TMS (HF-rTMS). Clinical advantages include less time per intervention session and the effects appear to be more robust and reproducible than HF-rTMS to modulate cortical excitability. HF-rTMS targeted at the primary motor cortex (M1) has demonstrated analgesic effects in patients with neuropathic pain but their mechanisms of action are unclear and pcTBS has been studied in healthy subjects only. This study examined the neural mechanisms that have been proposed to play a role in explaining the effects of pcTBS targeted at the M1 and DLPFC brain regions in neuropathic pain (NP) patients with Type 2 diabetes.
Forty-two patients with painful diabetic neuropathy were randomized to receive a single session of pcTBS targeted at the left M1 or left DLPFC. pcTBS stimulation consisted of 1,200 pulses delivered in 1 min and 44 s with a 35–45 min gap between sham and active pcTBS stimulation. Both the activity of the descending pain system which was examined using conditioned pain modulation and the activity of the ascending pain system which was assessed using temporal summation of pain were recorded using a handheld pressure algometer by measuring pressure pain thresholds. The amplitude of the motor evoked potential (MEP) was used to measure motor corticospinal excitability and GABA activity was assessed using short (SICI) and long intracortical inhibition (LICI). All these measurements were performed at baseline and post-pcTBS stimulation.
Following a single session of pcTBS targeted at M1 and DLPFC, there was no change in BPI-DN scores and on the activity of the descending (measured using conditioned pain modulation) and ascending pain systems (measured using temporal summation of pain) compared to baseline but there was a significant improvement of >13% in perception of acute pain intensity, increased motor corticospinal excitability (measured using MEP amplitude) and intracortical inhibition (measured using SICI and LICI).
In patients with NP, a single session of pcTBS targeted at the M1 and DLPFC modulated the neurophysiological mechanisms related to motor corticospinal excitability and neurochemical mechanisms linked to GABA activity, but it did not modulate the activity of the ascending and descending endogenous modulatory systems. In addition, although BPI-DN scores did not change, there was a 13% improvement in self-reported perception of acute pain intensity.